Corbus Pharmaceuticals (CRBP)

• Market cap: $146M
• 1 day: -1.19%
• 5 days: 2.21%
• 1 month: -29.88%
• 3 months: -31.21%
• 6 months: 3.87%
• Year to date: -30.81%
• 1 year: -36.61%
• 5 years: -77.96%
• 10 years: -82.97%
• Sector: Healthcare
• Industry: Biotechnology

About: Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Employees: 28